PT - JOURNAL ARTICLE AU - Shenoy, Padmanabha AU - Ahmed, Sakir AU - Cherian, Somy AU - Paul, Aby AU - Shenoy, Veena AU - Vijayan, Anuroopa AU - Reji, Reshma AU - Thampi, Arya AU - Sageer Babu, AS AU - Mohan, Manju TI - Immunogenicity of the ChAdOx1 nCoV-19 and the BBV152 Vaccines in Patients with Autoimmune Rheumatic Diseases AID - 10.1101/2021.06.06.21258417 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.06.21258417 4099 - http://medrxiv.org/content/early/2021/06/07/2021.06.06.21258417.short 4100 - http://medrxiv.org/content/early/2021/06/07/2021.06.06.21258417.full AB - Introduction There is limited information on the effectiveness of COVID-19 vaccination in patients with autoimmune rheumatic diseases (AIRD).Methods 136 consecutive patients with rheumatic diseases who never had a diagnosis of COVID-19 previously, and had completed vaccination with either the ChAdOx1 or BBV152 vaccines were recruited. Their IgG antibody titres to the Spike protein were estimated 1 month after the second dose.Results 102 patients had AIRD while the 34 had non-AIRD. Lesser patients with AIRD (92/102) had positive antibodies titres than ones with non-AIRD(33/34) [p<0.001]. Amongst patients who received the ChAdOX1 vaccine, the AIRD group had lower antibody titres. Although the AIRD patients receiving BBV152 had similarly lower titres numerically, this did not attain statistical significance probably due to lesser numbers. Comparing the two vaccines, 114(95%) of those who received ChAdOx1 (n=120) and 11(68.7%) of those who received BBV152(n=16) had detectable antibodies [p=0.004]. Antibody titres also were higher in ChAdOx1 recipients when compared to BBV152.To validate the findings, we estimated antibody titres in 30 healthy people each who had received either vaccine. All 30 who had received ChAdOX1 and only 23/30 of those who had received BBV152 had positive antibodies (p=0.011).Conclusion In this preliminary analysis, patients with AIRD had lower seroconversion rates as well as lower antibody titres as compared to patients with non-AIRD. Also,the humoral immunogenicity of the BBV152 vaccine appears to be less than that of the ChAdOX1 vaccine. Validation using larger numbers and testing of cellular immunity is urgently required.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNilAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics Committee of Sree Sudheendra Medical Mission Hospital No: IEC/2021/35)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available and all authors have seen it